EMPLICITI (elotuzumab) Patient Assistance Program
Don’t let the high cost of brand specialty myeloma therapy stand between you and the treatment you need. We help eligible patients access Empliciti (elotuzumab) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Empliciti (elotuzumab) is FDA-approved in combination with lenalidomide and dexamethasone for adults with multiple myeloma who have received one to three prior therapies, and in combination with pomalidomide and dexamethasone for adults with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
- Without assistance, the list price for an Empliciti vial is approximately $2,275 for a 300 mg vial and approximately $3,031 for a 400 mg vial. Per-infusion costs vary based on body weight (dosing is 10 mg/kg) and infusion-site billing — commonly running into the four to five figures per infusion.
- Through AffordMyPrescriptions, qualifying patients can access Empliciti coverage for a flat $69.95 per month — our advocacy team manages the entire enrollment, infusions, and renewal process.
- There is no generic or biosimilar version of Empliciti available in the U.S. as of 2026.
What is Empliciti Prescription Assistance Program?
The Empliciti Prescription Assistance Program is a manufacturer-sponsored initiative that provides Empliciti infusions at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for myeloma patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries who cannot afford specialty oncology infusion therapy.
Navigating the program on your own means dealing with eligibility verification, oncology-team coordination, prior-authorization documentation, infusion scheduling alongside oral myeloma medicines, and renewal deadlines — all while managing relapsed or refractory myeloma.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through infusion-schedule coordination and annual re-certification — so you focus on your treatment, not paperwork.
Pharmacy Price Comparison
- Without assistance, Empliciti infusions cost roughly $2,275–$3,031 per vial, with multiple vials used per infusion based on body weight. Pharmacy discount coupons are not a meaningful tool for IV therapy. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| 300 mg vial (list price) | ~$2,275.00 | Save ~$2,205/dose |
| 400 mg vial (list price) | ~$3,031.00 | Save ~$2,961/dose |
| Typical 70kg patient/infusion | ~$5,300+ | Save thousands/infusion |
| Weekly during cycles 1-2 | ~$5,300/wk | Save ~$5,230/wk |
| Annual treatment cost | ~$130,000+ | Save ~$129,000+/yr |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. Afford My Prescriptions Advocacy Service bypasses retail pricing by using drug manufacturer programs to secure your medication for you—independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Empliciti Prescription Program?
The Patient Assistance Program is free to apply for and provides Empliciti infusions at little or no medication cost if approved. But the process involves detailed applications, oncology-team coordination, prior-authorization documentation, and ongoing renewal management — particularly important for a weight-based weekly infusion regimen. Our $69.95/month service covers full advocacy: applications, doctor coordination, infusion scheduling, documentation, and annual re-enrollment — so you focus on your treatment, not paperwork.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Empliciti:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Manufacturer delivery program excludes insurance use
Coupon cards expire and require constant renewal
Still $2,275–$3,031 per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Empliciti assistance.
- You are a U.S. citizen or legal resident
- You Have A Valid Empliciti Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured Or Underinsured And Cannot Afford Your Medication
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Empliciti:
Empliciti (elotuzumab) is an intravenous (IV) immunotherapy medicine used to treat adults with multiple myeloma. It is given by infusion in combination with other myeloma therapies on a defined schedule set by the oncology team. The two FDA-approved combinations are Empliciti with lenalidomide and dexamethasone (after one to three prior therapies) and Empliciti with pomalidomide and dexamethasone (after at least two prior therapies including lenalidomide and a proteasome inhibitor).
How It Works:
Empliciti is a monoclonal antibody that targets SLAMF7, a marker found on both myeloma cells and natural killer (NK) cells. It functions through a dual mechanism: it directly activates NK cells to better recognize cancer and simultaneously “flags” myeloma cells for destruction by the immune system. This process triggers immune-mediated killing, specifically through antibody-dependent cellular cytotoxicity and phagocytosis.
Form and Use:
Administered via IV infusion in a clinical setting, Empliciti dosing is weight-based at 10 mg/kg. The schedule typically involves weekly infusions for the first two cycles, followed by bi-weekly doses, always in combination with other medications like dexamethasone and lenalidomide. To minimize the risk of infusion reactions, patients receive specific premedication before each treatment session.
Generic Availability:
As of 2026, there are no FDA-approved generic or biosimilar versions of Empliciti available in the United States. Since it is a biologic medicine, any future competition would come in the form of a biosimilar rather than a traditional small-molecule generic. While other therapies targeting different antigens exist, such as anti-CD38 antibodies, the choice of treatment remains a specialized decision for an oncology team.
Warnings:
The primary warnings associated with Empliciti include infusion reactions, which affect about 10 percent of patients, and an increased risk of infections. Other concerns involve liver toxicity, the potential for secondary cancers, and interference with lab tests used to monitor myeloma progress. Due to these risks, healthcare teams require premedication and will monitor patients closely to adjust or pause therapy if necessary.
FAQ (Frequently Asked Questions)
How Much Does Empliciti Cost Without Insurance
The list price for a 300 mg Empliciti vial is approximately $2,275, and for a 400 mg vial approximately $3,031. Because dosing is weight-based at 10 mg/kg, the number of vials used per infusion varies, and per-infusion totals commonly run into the four to five figures. Through AffordMyPrescriptions, qualifying patients receive Empliciti infusions at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
What Should I Expect At My First Infusion?
Premedication is given before each Empliciti infusion to lower the risk of infusion reactions, which occurred in approximately 10 percent of patients in clinical trials and were most common with the first dose. Symptoms can include fever, chills, or shortness of breath, and the infusion team is trained to manage them. Plan for a longer first infusion than later ones.
Are There Other Myeloma Therapies I Should Know About?
Yes. Multiple myeloma treatment includes monoclonal antibodies (Empliciti targets SLAMF7; other antibodies target CD38), immunomodulatory drugs, proteasome inhibitors, and BCMA-directed therapies, used in many different combinations. Whether any of these is a better clinical fit than Empliciti for your specific situation is a decision for your oncology team.
Can I Get Empliciti Through The PAP If I Have Medicare?
Yes. Medicare beneficiaries can typically qualify for Empliciti Patient Assistance, especially if you face significant out-of-pocket costs under medical or pharmacy benefits. The manufacturer’s commercial copay assistance program ($0 per infusion, up to ~$25,000/year) is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
What if my application is denied?
If your initial application is denied, we explore alternative savings paths on your behalf — including independent oncology- and myeloma-focused foundations such as the PAN Foundation, HealthWell Foundation, International Myeloma Foundation, Multiple Myeloma Research Foundation, or Leukemia & Lymphoma Society, the manufacturer’s copay assistance program if you have commercial insurance, or asking your oncology team whether a different myeloma combination on a more accessible cost path would be appropriate. If we cannot find a path to medication access, you will not be charged our service fee.
How Long Does It Take To Get Approved?
Most enrolled patients see their first covered Empliciti infusion within two to four weeks of completing the documentation. Timing depends on how quickly your oncology team returns the required forms and the program processes your application.
Take Control of Your Medication Costs
If you are struggling with the high cost of Empliciti, our team may be able to help you access assistance programs designed to make brand specialty myeloma therapy affordable. Check your eligibility today and take the first step toward predictable, sustainable treatment.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.